|
1) Sartor RB. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol. 2006; 3: 390-407
|
|
|
|
2) Mowat C, Cole A, Windsor A, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2011; 60: 571-607
|
|
|
|
|
|
3) Hanauer SB. Inflammatory bowel disease. N Engl J Med. 1996; 334: 841-8
|
|
|
|
|
|
4) Ito H, Iida M, Matsumoto T, et al. Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind, randomized study. Inflamm Bowel Dis. 2010; 16: 1567-74
|
|
|
|
|
|
5) Hiwatashi N, Suzuki Y, Mitsuyama K, et al. Clinical trial: Effects of an oral preparation of mesalazine at 4 g/day on moderately active ulcerative colitis. A phase III parallel-dosing study. J Gastroenterol. 2010; 46: 46-56
|
|
|
|
|
6) Marteau P, Probert CS, Lindgren S, et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut. 2005; 54: 960-5
|
|
|
|
|
|
7) Dignass AU, Bokemeyer B, Adamek H, et al. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. Clin Gastroenterol Hepatol. 2009; 7: 762-9
|
|
|
|
|
|
8) Sakuraba A, Motoya S, Watanabe K, et al. An open-label prospective randomized multicenter study shows very rapid remission of ulcerative colitis by intensive granulocyte and monocyte adsorptive apheresis as compared with routine weekly treatment. Am J Gastroenterol. 2009; 104: 2990-5
|
|
|
|
|
|
9) Yamamoto T, Umegae S, Matsumoto K. Daily granulocyte and monocyte adsorptive apheresis in patients with active ulcerative colitis: a prospective safety and feasibility study. J Gastroenterol. 2011: 46: 1003-9
|
|
|
|
|
|
10) Sands BE, Sandborn WJ, Feagan B, et al. A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis. Gastroenterology. 2008; 135: 400-9
|
|
|
|
|
|
11) Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994; 330: 1841-5
|
|
|
|
|
|
12) Kobayashi T, Naganuma M, Okamoto S, et al. Rapid endoscopic improvement is important for 1-year avoidance of colectomy but not for the long-term prognosis in cyclosporine A treatment for ulcerative colitis. J Gastroenterol. 2010; 45: 1129-37
|
|
|
|
|
|
13) Ogata H, Matsui T, Nakamura M, et al. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut. 2006; 55: 1255-62
|
|
|
|
|
|
14) Sands BE, Tremaine WJ, Sandborn WJ, et al. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis. 2001; 7: 83-8
|
|
|
|
|
|
15) Probert CS, Hearing SD, Schreiber S, et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut. 2003; 52: 998-1002
|
|
|
|
|
|
16) Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005; 353: 2462-76
|
|
|
|
|
|
17) Burger DC, Travis S. Colon salvage therapy for acute severe colitis: cyclosporine or infliximab？ Curr. 2011; 27: 358-62
|
|
|
|
|